Syndax Pharmaceuticals : SNDX

SNDX

Stock Data

$19.11

$2.32 (10.83%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Syndax Pharmaceuticals Inc is a pioneering biopharmaceutical firm focused on crafting innovative therapies for cancer treatment. At the forefront of its development pipeline are revumenib, aimed at tackling acute leukemias and solid tumors, and axatilimab, designed for chronic graft versus host disease and idiopathic pulmonary fibrosis. Additionally, the company is advancing Entinostat, with strategic partnerships enhancing its global reach. Founded in 2005 and based in Waltham, Massachusetts, Syndax is committed to addressing unmet medical needs in oncology.

All Syndax Pharmaceuticals Articles

1 Article

Joel South | Mar 9, 2026 at 11:17 AM EDT

uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts

Wall Street is turning constructive on three clinical-stage biotechs simultaneously, each sitting at the edge of a binary catalyst. The…

Syndax Pharmaceuticals : SNDX

SNDX

$19.11

All Syndax Pharmaceuticals Articles

uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Warren Buffett’s Parting Gift to Investors Is Crushing the Market 6 Months Later

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s

College-Educated Families Earned $242,200 While Others Made $42,200, Here's Why the Gap Widened

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Syndax Pharmaceuticals : SNDX

SNDX

$19.11

All Syndax Pharmaceuticals Articles

uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Warren Buffett’s Parting Gift to Investors Is Crushing the Market 6 Months Later

Featured Reads

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s

College-Educated Families Earned $242,200 While Others Made $42,200, Here's Why the Gap Widened